// App-Quantinova.ai

1600 : Real‐world effectiveness and cost per svr of sofosbuvir/velpatasvir chronic hepatitis c treatment

Researchers

Presenter

  • Peter Buaaisch

Principal Investigators

  • Petar Atanasov

  • Karsten Wursthorn

  • Albrecht Stoehr

  • Joerg Petersen

Medical Centers

  • Asklepios Klinik St. Georg, IFI Institut für Interdisziplinäre Medizin, Hamburg, Germany

  • NCRI, London, United Kingdom

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis C

Biomarkers

  • Sustained virological response

Drug/Treatment

  • Velpatasvir/sofosbuvir

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved